Top

Published in:

01-07-2017 | Letter to the Editor

The value of algorithms predicting the Oncotype DX recurrence score should not be underestimated!

Authors: Bradley Turner, Ping Tang, David Hicks

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Excerpt

In a recent issue, Harowicz et al. [1] retrospectively analyzed 305 patients with invasive breast cancer using three equations developed by Klein et al., a fourth equation developed by Gage et al., and a fifth equation developed by Tang et al. All five equations use estrogen receptor (ER) and progesterone receptor (PR) status along with different combinations of grade, proliferation indices (Ki-67, mitotic rate), HER2 status, and tumor size. The authors concluded that “although commonly available surrogates for Oncotype DX appear to predict high-risk Oncotype DX recurrence score, they are unable to reliably rule out the presence of patients with intermediate-risk disease by Oncotype DX” [1]. …

Harowicz MR, Robinson TJ, Dinan MA et al (2017) Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Res Treat 162(1):1–10CrossRefPubMed

Turner BM, Skinner KA, Tang P et al (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol 28(7):921–931CrossRefPubMed

Klein ME, Dabbs DJ, Shuai Y et al (2013) Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol 26(5):658–664CrossRefPubMedPubMedCentral

Title: The value of algorithms predicting the Oncotype DX recurrence score should not be underestimated!
Authors: Bradley Turner
Ping Tang
David Hicks
Publication date: 01-07-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4236-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression

Squamous cell carcinoma of the breast in the United States: incidence, demographics, tumor characteristics, and survival

Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer